A-205804 对人内皮细胞黏附分子表达展现出显著的多靶点抑制活性：对E-选择素（SELE）的IC₅₀为0.02 μM，对细胞间黏附分子-1（ICAM-1）的IC₅₀为0.025 μM，二者均属显著活性水平；对血管细胞黏附分子-1（VCAM-1）的IC₅₀为1 μM，活性相对较弱 ^[2]。值得注意的是，A-205804在人脐静脉内皮细胞（HUVEC）裂解液中的细胞毒性IC₅₀为152 μM，提示在有效抑制黏附分子表达浓度范围内具有较高的细胞安全窗口 ^[2]。此外，A-205804在苯乙醇胺N-甲基转移酶（PNMT）的甲基转移酶靶点类别筛选中亦呈现抑制效应 ^[7]，进一步揭示其潜在的多靶点调控特性。

在大鼠体内药代动力学研究中，A-205804（给药途径、频率及持续时间据文献^[1]报告）的血浆峰浓度（Cmax）为0.25965 μM ^[1]，提示该化合物经给药后可在大鼠循环系统中达到与其体外抑制SELE和ICAM-1活性浓度相当的暴露水平，具有一定的体内暴露可行性 ^[1]。该化合物对血管内皮黏附分子的显著抑制特性提示其在LPS诱导的急性肺损伤小鼠模型中可能具有抑制炎症浸润和组织损伤的潜力；此外，其对ICAM-1和E-选择素的靶向抑制亦提示在炎症相关血管内皮激活模型中可能具有抗炎及减少白细胞募集的作用 ^[2]。

A-205804是一种具有显著活性的血管内皮黏附分子抑制剂，对SELE（IC₅₀ = 0.02 μM）和ICAM-1（IC₅₀ = 0.025 μM）展现出10–100 nM范围内的显著抑制活性，对VCAM-1（IC₅₀ = 1 μM）则呈中等抑制活性 ^[2]，三靶点间存在明显的选择性差异。大鼠体内Cmax达0.25965 μM，与体外有效浓度相近，提示其具备合理的体内暴露特征 ^[1]。HUVEC细胞毒性IC₅₀高达152 μM，安全窗宽广 ^[2]。甲基转移酶靶点类别筛选中，A-205804对PNMT亦显示抑制活性 ^[7]，提示其潜在的多靶点干预能力，整体药理特征以抗炎性黏附分子抑制为核心。

[1] Stewart AO, Bhatia PA, McCarty CM, Patel MV, Staeger MA, Arendsen DL, Gunawardana IW, Melcher LM, Zhu GD, Boyd SA, Fry DG, Cool BL, Kifle L, Lartey K, Marsh KC, Kempf-Grote AJ, Kilgannon P, Wisdom W, Meyer J, Gallatin WM, Okasinski GF. Discovery of inhibitors of cell adhesion molecule expression in human endothelial cells. 1. Selective inhibition of ICAM-1 and E-selectin expression. J Med Chem. 2001 Mar 15;44(6):988–1002. doi: 10.1021/jm000452m. PMID: 11300880.

[2] Zhu GD, Arendsen DL, Gunawardana IW, Boyd SA, Stewart AO, Fry DG, Cool BL, Kifle L, Schaefer V, Meuth J, Marsh KC, Kempf-Grote AJ, Kilgannon P, Gallatin WM, Okasinski GF. Selective inhibition of ICAM-1 and E-selectin expression in human endothelial cells. 2. Aryl modifications of 4-(aryloxy)thieno[2,3-c]pyridines with fine-tuning at C-2 carbamides. J Med Chem. 2001 Oct 11;44(21):3469–87. doi: 10.1021/jm0101702. PMID: 11585452.

[3] Abrams RPM, Yasgar A, Teramoto T, Lee MH, Dorjsuren D, Eastman RT, Malik N, Zakharov AV, Li W, Bachani M, Brimacombe K, Steiner JP, Hall MD, Balasubramanian A, Jadhav A, Padmanabhan R, Simeonov A, Nath A. Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. Proc Natl Acad Sci U S A. 2020 Dec 08;117(49):31365–75. PMID: 33229545; PMCID: PMC7733812.

[4] Lee OW, Austin S, Gamma M, Cheff DM, Lee TD, Wilson KM, Johnson J, Travers J, Braisted JC, Guha R, Klumpp-Thomas C, Shen M, Hall MD. Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. SLAS Discov. 2020 Jan;25(1):9–20. PMID: 31498718; PMCID: PMC10791069.

[5] Lee TD, Lee OW, Brimacombe KR, Chen L, Guha R, Lusvarghi S, Tebase BG, Klumpp-Thomas C, Robey RW, Ambudkar SV, Shen M, Gottesman MM, Hall MD. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular Pharmacology. 2019 Nov;96(5):629–40. doi: 10.1124/mol.119.115964.

[6] Henderson MJ, Trychta KA, Yang SM, Bäck S, Yasgar A, Wires ES, Danchik C, Yan X, Yano H, Shi L, Wu KJ, Wang AQ, Tao D, Zahoránszky-Kohalmi G, Hu X, Xu X, Maloney D, Zakharov AV, Rai G, Urano F, Airavaara M, Gavrilova O, Jadhav A, Wang Y, Simeonov A, Harvey BK. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell Rep. 2021 Apr 27;35(4):109040. PMID: 33910017; PMCID: PMC8545458.

[7] Hanson QM, Hoxie N, Shen M, Guo H, Cho IJ, Chakraborty I, Aragon BM, Rai G, Patnaik S, Janiszewski JS, Hall MD. Target Class Profiling of Small-Molecule Methyltransferases. ACS Chem Biol. 2023 Apr 21;18(4):969–81. PMID: 36976909; PMCID: PMC10983791.